• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by POMDOCTOR LIMITED

    12/3/25 4:15:30 PM ET
    $POM
    Other Specialty Stores
    Consumer Discretionary
    Get the next $POM alert in real time by email
    6-K 1 ea0268059-6k_pomdoc.htm REPORT OF FOREIGN PRIVATE ISSUER

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

    THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of December 2025

     

    Commission File Number: 001-42749

     

    POMDOCTOR LIMITED

    (Exact name of registrant as specified in its charter)

     

    Yongxu Industrial Park
    No.19-23 Hejing Road, Dongsha Street
    Liwan District, Guangzhou 510000

    People’s Republic of China

    (Address of principal executive office)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

     

    Form 20-F ☒ Form 40-F ☐

     

     

     

     

     

     

    EXHIBIT INDEX

     

    Exhibit No.   Description
    99.1   POMDOCTOR LIMITED Announces First Half of Fiscal 2025 Unaudited Financial Results

     

    1

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

      POMDOCTOR LIMITED
         
      By: /s/ Zhenyang Shi
      Name: Zhenyang Shi
      Title: Chairman and Chief Executive Officer

     

    Date: December 3, 2025

     

    2

     

    Get the next $POM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $POM

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $POM
    SEC Filings

    View All

    SEC Form 6-K filed by POMDOCTOR LIMITED

    6-K - POMDOCTOR Ltd (0001877971) (Filer)

    12/3/25 4:15:30 PM ET
    $POM
    Other Specialty Stores
    Consumer Discretionary

    SEC Form S-8 filed by POMDOCTOR LIMITED

    S-8 - POMDOCTOR Ltd (0001877971) (Filer)

    11/5/25 4:00:55 PM ET
    $POM
    Other Specialty Stores
    Consumer Discretionary

    $POM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    POMDOCTOR LIMITED Announces First Half of Fiscal 2025 Unaudited Financial Results

    GUANGZHOU, China, Dec. 3, 2025 /PRNewswire/ -- Pomdoctor Limited ("Pomdoctor" or the "Company") (NASDAQ:POM), a leading online medical services platform for chronic diseases in China, today announced its unaudited financial results for the six months ended June 30, 2025. Mr. Zhenyang Shi, Chairman and Chief Executive Officer of Pomdoctor, commented: "The first half of fiscal year 2025 reflected our deliberate and disciplined efforts to balance business expansion with operational rigor. Despite a challenging macroeconomic environment and intensified market competition, we strived to strengthen our market coverage and penetration, while optimizing and diversifying our revenue streams through

    12/3/25 4:15:00 PM ET
    $POM
    Other Specialty Stores
    Consumer Discretionary

    POMDOCTOR LIMITED Announces Full Exercise and Closing of Underwriter's Over-Allotment Option

    GUANGZHOU, China, Oct. 10, 2025 /PRNewswire/ -- POMDOCTOR LIMITED (NASDAQ:POM) (the "Company" or "POMDOCTOR"), a leading online medical services platform for chronic diseases in China, today announced the underwriter of its initial public offering (the "Offering") has exercised in full its option to purchase an additional 750,000 American Depositary Shares ("ADSs") at a public offering price of $4.00 per ADS to cover over-allotments. Six ADSs represent one Class A ordinary share, par value US$0.0001 per share, of the Company. Gross proceeds to the Company from the offering, including funds received from the prior closing and exercise of this over-allotment option, totaled $23,000,016, before

    10/10/25 5:15:00 PM ET
    $POM
    Other Specialty Stores
    Consumer Discretionary